Caso de Estudio

Using ERG to Monitor Glaucoma

by Dr. Edith Rom, Augenarztpraxis Dr. Domscheit & Dr. Neißkenwirth, Germany

A 62-year-old female presented with high myopia, low-tension glaucoma with recurrent disc margin hemorrhages, progressive thinning of the optic nerve rims, and visual field defects. She received multiple treatments over a 3-month period. These included topical IOP-lowering medications, acupuncture, and laser trabeculoplasty.

Glaucoma Case Study by Dr. Edith Rom, Germany

Challenge100px
Desafío

Confirm treatment success

Eye100px
DIAGNÓSTICO

Glaucoma

CSNB 100px
Type of Protocol

PhNR

ONH (OD) ONH (OS)

 

¿Por qué se realizó la prueba ERG?

Establishing treatment success in patients with progressive glaucoma is very challenging. In this case, the optic-disc cupping was continuously worsening, which made it difficult to determine treatment effect. The ERG provided a means to confirm whether or not the treatment plan was having a positive impact.

 

¿Cuáles fueron los hallazgos del ERG?

Just before we initiated treatment, the PhNR test parameters, as measured by the RETeval device, were outside the normal limits. After three months, all values improved and fell within the recommended reference ranges. Correspondingly, the patient also had slight contrast sensitivity improvements.

ERG (PhNR Protocol) before treatment ERG (PhNR Protocol) after treatment

Dispositivo RETeval ERG/VEP device and discuss this case study with the LKC Team.
Pass by our booth: H.39 at the upcoming Deutsche Ophthalmologische Gesellschaft (DOG) Congress
in Berlin, from 10 to 13 October.

Not going to DOG 2024? Contact us to learn more

¿Cómo influyó ERG en la atención al paciente?

The ERG findings provided peace of mind that we are on the right treatment path, but need to continue to closely monitor both structural and functional parameters in the event her condition worsens and requires additional intervention, such as surgery.
 

Conclusión

This case demonstrates how ERG provides useful information about changes to ganglion cell function that help us more easily monitor treatment effects. Having this additional sensitive parameter helps us decide if and when additional measures are needed or if the current approach is adequate in the short-term.